Prevalence and clinical application of TMPRSS2-ERG fusion in Asian prostate cancer patients: a large-sample study in Chinese people and a systematic review  

作　　者：De-Pei Kong Rui Chen Chun-Lei Zhang Wei Zhang Guang-An Xiao Fu-Bo Wang Na Ta Xu Gao Ying-Hao Sun 

机构地区：[1]Department of Urology,Shanghai Changhai Hospital,Second Military Medical University,Shanghai 200433,China [2]Department of Pathology,Shanghai Changhai Hospital,Second Military Medical University,Shanghai 200433,China

出　　处：《Asian Journal of Andrology》2020年第2期200-207,共8页亚洲男性学杂志（英文版）

基　　金：This research was funded by the National Nature Science Foundation Youth Project(Grant No.81702514);the National Natural Science Foundation of China(Grant No.81430058);the Clinical Research Project of Shanghai Municipal Commission of Health and Family Planning(Grant No.20184Y0130).

摘　　要：Fusion between the transmembrane protease serine 2 and v-ets erythroblastosis virus E26 oncogene homolog(TMPRSS2-ERG fusion)is a common genetic alteration in prostate cancer among Western populations and has been suggested as playing a role in tumorigenesis and progression of prostate cancer.However,the prevalence of TMPRSS2-ERG fusion differs among different ethnic groups,and contradictory results have been reported in Asian patients.We aim to evaluate the prevalence and significance of TMPRSS2-ERG fusion as a molecular subtyping and prognosis indicator of prostate cancer in Asians.We identified the fusion status in 669 samples from prostate biopsy and radical prostatectomy by fluorescence in situ hybridization and/or immunohistochemistry in China.We examined the association of TMPRSS2-ERG fusion with clinicopathological characteristics and biochemical recurrence by Chi-square test and Kaplan–Meier analysis.Finally,a systematic review was performed to investigate the positive rate of the fusion in Asian prostate cancer patients.McNemar’s test was employed to compare the positive rates of TMPRSS2-ERG fusion detected using different methods.The positive rates of TMPRSS2-ERG fusion were 16%in our samples and 27%in Asian patients.In our samples,9.4%and 19.3%of cases were recognized as fusion positive by fluorescence in situ hybridization and immunohistochemistry,respectively.No significant association between the fusion and clinical parameters was observed.TMPRSS2-ERG fusion is not a frequent genomic alteration among Asian prostate cancer patients and has limited significance in clinical practices in China.Besides ethnic difference,detection methods potentially influence the results showing a positive rate of TMPRSS2-ERG fusion.

关 键 词：ASIAN Chinese PROSTATE cancer systematic review TMPRSS2-ERG 

分 类 号：R737.25[医药卫生—肿瘤]